## REMARKS

### Claims Status

Claims 8-10 and 14-28 are pending. Claims 8-28 are now cancelled without prejudice to Applicants' right to pursue the subject matter contained therein in a future application. Applicants have also added new claims 29-43. Support for the new claims can be found, *inter alia*, in the canceled claims. Hence, Applicants submit no new matter has been added.

### Response To Advisory Action

In the Advisory Action mailed October 1, 2009, the Examiner contends that the prior art of record Columbo et al. in view of Vrtala et al. read on the amended claims filed on September 17, 2009 because SEQ ID NO:4 comprises mutations that are specifically taught on page 2782 second paragraph of Columbo et al. Applicants respectfully traverse.

First of all, Applicants submit that in the Final Office Action mailed June 2, 2009, claims 14-15 and 17-24 were rejected under 35 U.S.C. 103(a) as being unpatentable over Vrtala et al. in view of Columbo. The claims were not rejected based on Columbo et al. in view of Vrtala et al.

Secondly, Applicants submit that Columbo et al. do not read on SEQ ID NO:4. Second paragraph on page 2782 of Columbo et al. only teach mutants for Par j 1:

> In addition, the modeled structure of the Par j 1.0101 was used to identify potential amino acids residues directly involved in IgE binding. The region encompassing residues 1 to 30 was examined to

> identify any exposed side chains that would be capable of interacting with IgE. Residues Q19, K21, E22. K23, E24, and K27 were identified as potential candidates, and site-directed mutagenesis was used to mutate these residues to alanine. The IgE binding activity of the resultant mutants was tested by Western blot analysis (Fig. 3B). From this analysis we showed that mutation of the K21, K23, E24. and K27 amino acids caused loss of binding.

Hence, Applicants submit that Columbo et al. only teach mutants for Par j 1. The sequences and data presented in Columbo et al. are all derived from Par j 1 (*see e.g.* Figures 2-3). Columbo et al. do not teach or suggest any sequence for Par j 2 mutants as claimed herein.

In contrast, SEQ ID NO:4 of the present invention is a mutant of Par j 2. As taught in Columbo et al., Par j 1 and Par j 2 are two different polypeptides with different sequences and different molecular weights (*see* right column on page 2780). Columbo et al. do not teach a 102-amino acid sequence of SEQ ID NO:4 as claimed herein; neither do Vrtala et al. disclose such a 102-amino acid sequence. Hence, Applicants submit that the combination of Columbo and Vrtala does not render SEQ ID NO:4 of the present invention obvious because the combined teaching of the cited references does not teach or suggest a 102-amino acid sequence identical to SEQ ID NO:4 as claimed herein.

**CONCLUSION**

Applicants submit that the Amendment has fully addressed the Examiner's concerns expressed in the June 2, 2009 Office Action, and should not raise additional issues. Therefore, the application is in full compliance with all requirements. Accordingly, Applicants respectfully request the Examiner to put the application in condition for allowance.

If a telephone interview would be of assistance in advancing the prosecution of the subject application, Applicants' undersigned attorney invites the Examiner to telephone him at the number provided below. If any additional fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 50-1891.

Respectfully submitted,

Albert Wai-Kit Chan
Registration No. 36,479
Attorney for Applicants
Law Offices of
Albert Wai-Kit Chan, PLLC
World Plaza, Suite 604
141-07 20th Avenue
Whitestone, New York 11357
Tel: (718) 799-1000
Fax: (718) 357-8615
E-mail: chank@kitchanlaw.com